ReNeuron Group plc Directorate Change (7159D)
01 July 2021 - 4:00PM
UK Regulatory
TIDMRENE
RNS Number : 7159D
ReNeuron Group plc
01 July 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Directorate Change
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces today that Iain
Ross has joined as a Non-Executive Director and Chairman of the
Board of Directors with immediate effect. Dr. Tim Corn is stepping
down as Chairman of the Board of Directors, but will remain as a
Non-Executive Director.
Iain Ross is a highly experienced board director with a career
in the international life sciences and technology sectors that
spans 40 years. He held senior commercial roles at Sandoz, Fisons
and Hoffman La Roche before moving into the biotechnology sector
where he has been Chairman, CEO and Director of several
international biotechnology companies including Celltech Group plc,
Quadrant Healthcare plc and Redx Pharma plc.
Currently he is Non-Executive Chairman at Silence Therapeutics
PLC (LSE/NASDAQ) and Kazia Therapeutics Limited (ASX/NASDAQ). Mr
Ross is a qualified Chartered Director, Fellow of the Institute of
Directors and Honorary Fellow of Royal Holloway, London
University.
Olav Hellebø, Chief Executive Officer of ReNeuron, commented:
"We are delighted to welcome Iain to the ReNeuron team as
Non-Executive Director and Chairman. Iain has considerable
experience with commercially successful international lifescience
businesses and we welcome his support as we enter into a period
where we expect to reach important, data-driven value inflection
points across our programmes over the next 12 months. "
Iain Ross, Incoming Chairman of the Board of Directors at
ReNeuron, commented: "I am delighted to be joining Reneuron at such
a pivotal time and look forward to working with the Board &
Management and to ensuring a significant uplift in shareholder
value over the next few years."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Full name and age: Iain Gladstone Ross (aged 67)
Iain Ross does not currently hold any shares in ReNeuron.
Current Directorships or Partnerships:
-- Biomer Technology Limited
-- Gladstone Consultancy Partnership
-- Gladstone Partners Limited
-- Kazia Therapeutics Limited
-- Palla Pharma Ltd
-- Silence Therapeutics PLC
Previous Directorships or Partnerships:
-- Aldershot Town Football Club Limited
-- Anatara Life Sciences Ltd
-- Benitec Biopharma Limited
-- E-Therapeutics plc
-- Innopeg Limited
-- Pharminox Limited
-- Premier Veterinary Group plc
-- Redx Immunology Limited
-- Redx Oncology Ltd
-- Redx Pharma plc
-- Redx Anti-Infectives Ltd
-- Redx MRSA Limited
-- Rosscard Leisure Limited
-- Silence Therapeutics (London) Ltd
-- Tacere Therapeutics Inc
-- Yellowcross Limited
Iain Ross joined the board of Redx Pharma plc on 1 May 2017. On
24 May 2017, Redx Pharma plc and Redx Oncology Ltd were put into
administration by Liverpool City Council as a result of non-payment
of an outstanding loan of GBP2m and shares in Redx Pharma plc were
suspended. On 3 November 2017 Redx Pharma plc and Redx Oncology Ltd
exited administration with all creditors paid and trading in Redx
Pharma plc resumed, under the Chairmanship of Iain Ross.
No further information in connection with the appointment of
Iain Ross is required to be disclosed under Schedule Two, paragraph
(g) of the Aim Rules for Companies.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments for disease with significant unmet
needs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the central nervous system and other disorders. The
Company also has the ability through its conditionally immortalised
induced pluripotent stem cell (iPSC) platform to make allogeneic
tissue cells of choice; in-house programmes are currently focused
on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABUGDLGGXDGBG
(END) Dow Jones Newswires
July 01, 2021 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024